BackgroundCardiac remodeling is a specific response to exercise training and time
exposure. We hypothesized that athletes engaging for long periods in
high-intensity strength training show heart and/or vascular damage.ObjectiveTo compare cardiac characteristics (structure and function) and vascular
function (flow-mediated dilation [FMD] and peripheral vascular
resistance [PVR]) in powerlifters and long-distance
runners.MethodsWe evaluated 40 high-performance athletes (powerlifters [PG], n
= 16; runners [RG], n = 24) and assessed heart structure and
function (echocardiography), systolic and diastolic blood pressure
(SBP/DBP), FMD, PVR, maximum force (squat, bench press, and deadlift), and
maximal oxygen uptake (spirometry). A Student’s t Test for independent
samples and Pearson’s linear correlation were used (p < 0.05).ResultsPG showed higher SBP/DBP (p < 0.001); greater interventricular septum
thickness (p < 0.001), posterior wall thickness (p < 0.001) and LV
mass (p < 0.001). After adjusting LV mass by body surface area (BSA), no
difference was observed. As for diastolic function, LV diastolic volume,
wave E, wave e’, and E/e’ ratio were similar for both groups. However, LA
volume (p = 0.016) and BSA-adjusted LA volume were lower in PG (p <
0.001). Systolic function (end-systolic volume and ejection fraction), and
FMD were similar in both groups. However, higher PVR in PG was observed (p =
0.014). We found a correlation between the main cardiovascular changes and
total weight lifted in PG.ConclusionsCardiovascular adaptations are dependent on training modality and the
borderline structural cardiac changes are not accompanied by impaired
function in powerlifters. However, a mild increase in blood pressure seems
to be related to PVR rather than endothelial function.
BackgroundHypertension is an important risk factor for cardiovascular outcomes. Primary
health care (PHC) physicians should be prepared to act appropriately in the
prevention of cardiovascular risk factors. However, the rates of patients
with control of blood pressure (BP) remain low. The impact of the
reclassification of high BP by 24-hour ambulatory BP monitoring (ABPM) can
lead to different medical decisions in PHC.ObjectiveTo evaluate the agreement between the BP measured by a conventional method by
PHC physicians and by 24-hour ABPM, considering different BP normal
thresholds for the 24-hour ABPM according to the V Brazilian ABPM Guidelines
and the European Society of Hypertension Guidelines.MethodsA cross-sectional study including 569 hypertensive patients. The BP was
initially measured by the PHC physicians and, later, by 24-hour ABPM. The BP
measurements were obtained independently between the two methods. The
therapeutic targets for the conventional BP followed the guidelines by the
Eighth Joint National Committee (JNC 8), the V ABPM Brazilian Guidelines,
and the 2013 European Hypertension Guidelines.ResultsThere was an accuracy of 54.8% (95% confidence interval [95%CI] 0.51 - 0.58%)
for the BP measured with the conventional method when compared with the
24-hour ABPM, with a sensitivity of 85% (95%CI 80.8 - 88.6%), specificity of
31.9% (95%CI 28.7 - 34.7%), and kappa value of 0.155, when considering the
European Hypertension Guidelines. When using more stringent thresholds to
characterize the BP as "normal" by ABPM, the accuracy was 45% (95%CI 0.41 -
0.47%) for conventional measurement when compared with 24-hour ABPM, with a
sensitivity of 86.7% (95%CI 0.81 - 0.91%), specificity of 29% (95%CI 0.26 -
0.30%), and kappa value of 0.103.ConclusionThe BP measurements obtained by PHC physicians showed low accuracy when
compared with those obtained by 24-hour ABPM, regardless of the threshold
set by the different guidelines.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.